Finding – Page 21

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss in Phase 1 Trial

1 year ago talkbio0Tagged Agonist, Laridae, Obesity, Oral cavity, phase 1 trial, TERN-601, Weight Loss

Terns Pharmaceuticals, TERN-601, Oral GLP-1R Agonist, Phase 1 Trial, Weight Loss, Obesity Treatment

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

1 year ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation

FDA Limits Use of Invivyd’s COVID-19 Prophylactic as New Variants Dominate

1 year ago talkbio0Tagged authorization, COVID19 (disease), Emergency Situation, Immunocompromised Host, Invivyd, Pemgarda, United States Food and Drug Administration, Variant

Invivyd, COVID-19, Pemgarda, Emergency Use Authorization, FDA, Immunocompromised, Variants

Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action

1 year ago talkbio0Tagged Contact Role - Federal Agency, Gegenhalten, Health care facility, Johnson & Johnson, Policy, Programs - Publication Format, Rebate Model

340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy

Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults

1 year ago talkbio0Tagged Adult, Diabetes, Eli, Eli Lilly, Mounjaro, Obesity, Overweight, Prediabetes syndrome, Risk Reduction, Sustained, Weight Loss, Zepbound

tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

1 year ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Novartis’ Fabhalta Clinches Another FDA Win, This Time in IgA Nephropathy

1 year ago talkbio0Tagged Approved, Complement Inactivating Agents, Fabhalta, IGA Glomerulonephritis, Novartis, Proteinuria, United States Food and Drug Administration

Novartis, Fabhalta, FDA approval, IgA nephropathy, proteinuria reduction, complement inhibitor, kidney disease

Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment

1 year ago talkbio0Tagged Agencies, Apellis, Approved, C3 glomerulopathy, Clinical Research, European (ethnic group), membranoproliferative glomerulonephritis, Proteinuria, Sobi, United States Food and Drug Administration

Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency